Canakinumab is effective as a first-line steroid-free treatment for patients with systemic juvenile idiopathic arthritis

Rheumatoid Arthritis

Which advanced treatment should be used following the failure of a first-line anti-TNF in patients with rheumatoid arthritis? 15 years of evidence from the Quebec registry RHUMADATA

Rheumatology (Oxford)

Choquette D, Haraoui B, Movahedi M, Bessette L, Sauvageau LC, Ferdinand I, Joly-Chevrier M, Masetto A, Massicotte F, Nadon V, Pelletier JP, Raynauld JP, Sauvageau D, Villeneuve É, Coupal L

doi: 10.1093/rheumatology/keae283

Juvenile Idiopathic Arthritis

Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study

Ann Rheum Dis

Brunner HI, Akikusa JD, Al-Abadi E, Bohnsack JF, Boteanu AL, Chedeville G, Cuttica R, De La Pena W, Jung L, Kasapcopur O, Kobusinska K, Schulert GS, Neiva C, Rivas-Chacon R, Rizo Rodriguez JC, Vazquez-Del Mercado M, Wagner-Weiner L, Weiss JE, Wouters C, Posner H, Wouters A, Chang C, White C, Kanik K, Liu S, Martini A, Lovell DJ, Ruperto N

doi: 10.1136/ard-2023-225094

Juvenile Idiopathic Arthritis

Integration of genetic and clinical risk factors improves the risk classification of uveitis in patients with juvenile idiopathic arthritis

Arthritis Rheumatol

Tordoff M, Smith SL, Lawson-Tovey S, UK JIA Biologics Register, CAPS, CHARMS, CLUSTER, JIAGC, Dick AD, Beresford MW, Ramanan AV, Hyrich KL, Morris AP, Eyre S, Wedderburn LR, Bowes J, CLUSTER consortium

doi: 10.1002/art.42955

Juvenile Idiopathic Arthritis

Factors for Consideration by Pediatric Rheumatologists When Scoring the Physician Global Assessment (PhGA) of Disease Activity in Juvenile Idiopathic Arthritis: First Step Toward an Internal Consensus

Arthritis Care Res (Hoboken)

Tarkiainen M, Balay-Dustrude E, Consolaro A, Morgan EM, Ruperto N, Rypdal V, Backström M, Vähäsalo P, Gottlieb BS, Paediatric Rheumatology International Trials Organisation, and the Pediatric Rheumatology Care & Outcomes Improvement Network and the PhGA consensus task force, For the Pediatric Rheumatology European Society (PRES) JIA working party

doi: 10.1002/acr.25447

Systemic Lupus Erythematosus

Treatment of systemic lupus erythematosus: Analysis of treatment patterns in adult and paediatric patients across four European countries

Eur J Intern Med

Du M, Dernie F, Català M, Delmestri A, Man WY, Brash JT, van Ballegooijen H, Mercadé-Besora N, Duarte-Salles T, Mayer MA, Leis A, Ramírez-Anguita JM, Griffier R, Verdy G, Prats-Uribe A, Pacurariu A, Morales DR, De Lisa R, Galluzzo S, Egger GF, Prieto-Alhambra D, Tan EH

doi: 10.1016/j.ejim.2024.08.008

Psoriatic ArthritisRheumatoid Arthritis

The effect of biological treatment on female fertility: A cohort study of women with rheumatoid arthritis and psoriatic arthritis

Semin Arthritis Rheum

Herzberger EH, Hornik-Lurie T, Levi Y, Miller N, Wiser A, Hershko-Klement A

doi: 10.1016/j.semarthrit.2024.152608

Rheumatoid Arthritis

Association of patient- and hospital-level predictors with patterns of initial treatment in patients with Rheumatoid Arthritis: findings from a national cohort study

Rheumatology (Oxford)

Yang Z, Alveyn E, Russell M, Bechman K, Coalwood C, Price E, Abhishek A, Norton S, Galloway J

doi: 10.1093/rheumatology/keae717

Juvenile Idiopathic Arthritis

Systemic juvenile idiopathic arthritis and adult-onset Still's disease are the same disease: evidence from systematic reviews and meta-analyses informing the 2023 EULAR/PReS recommendations for the diagnosis and management of Still's disease

Ann Rheum Dis

De Matteis A, Bindoli S, De Benedetti F, Carmona L, Fautrel B, Mitrovic S

doi: 10.1136/ard-2024-225853

Juvenile Idiopathic Arthritis

Transcriptomic profiling and immuno-histological characterization of synovial biopsies in juvenile idiopathic arthritis (JIA) suggest two broad categories, with significant overlap with rheumatoid arthritis (RA)

Arthritis Rheumatol

Triaille C, Tilman G, Baert CA, Sokolova T, Loriot A, Nzeusseu-Toukap A, Meric de Bellefon L, Galant C, Boulanger C, Fonseca JE, Bouzin C, Durez P, Lauwerys BR, Limaye N

doi: 10.1002/art.42922

Related content

Which advanced treatment should be used following the failure of a first-line anti-TNF in patients with rheumatoid arthritis? 15 years of evidence from the Quebec registry RHUMADATA

Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study

Integration of genetic and clinical risk factors improves the risk classification of uveitis in patients with juvenile idiopathic arthritis

Factors for Consideration by Pediatric Rheumatologists When Scoring the Physician Global Assessment (PhGA) of Disease Activity in Juvenile Idiopathic Arthritis: First Step Toward an Internal Consensus

Treatment of systemic lupus erythematosus: Analysis of treatment patterns in adult and paediatric patients across four European countries

The effect of biological treatment on female fertility: A cohort study of women with rheumatoid arthritis and psoriatic arthritis

Association of patient- and hospital-level predictors with patterns of initial treatment in patients with Rheumatoid Arthritis: findings from a national cohort study

Systemic juvenile idiopathic arthritis and adult-onset Still's disease are the same disease: evidence from systematic reviews and meta-analyses informing the 2023 EULAR/PReS recommendations for the diagnosis and management of Still's disease

Transcriptomic profiling and immuno-histological characterization of synovial biopsies in juvenile idiopathic arthritis (JIA) suggest two broad categories, with significant overlap with rheumatoid arthritis (RA)